Cytochroma

company

About

Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat

  • 51 - 100

Details

Last Funding Type
Series B
Last Funding Money Raised
$3.50M
Industries
Biotechnology,Clinical Trials,Pharmaceutical
Founded date
Jan 1, 1996
Number Of Employee
51 - 100
Operating Status
Close

Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$48.50M $7.60M
Cytochroma has raised a total of $48.50M $7.60M in funding over 2 rounds. Their latest funding was raised on Jul 30, 2008 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 30, 2008 Series C $45M 1 Detail
Dec 18, 2001 Series B $3.50M 3 Detail
Oct 30, 2001 Series B $7.60M 1 Detail
Feb 1, 1999 Series A 1 Detail

Investors

Number of Lead Investors
Number of Investors
3
Cytochroma is funded by 3 investors. Canadian Medical Discoveries Fund and CDP Sofinov are the most recent investors.
Investor Name Lead Investor Funding Round
Canadian Medical Discoveries Fund Series C
CDP Sofinov Series B
T2C2 Capital Series B